3 minute read1/1/2026animal
Understanding ligand selectivity and efficacy at melatonin (MT 1 , MT 2 ) and serotonin (5-HT 2C ) receptors remains a key challenge in central nervous system (CNS) drug discovery. Ligands combining MT 1 /MT 2 agonism with 5-HT 2C antagonism are of therapeutic relevance in depression and circadian rhythm disorders. This review provides a comprehensive overview of ligands reported for these receptors in ChEMBL, with an emphasis on compounds evaluated across multiple targets.
What the study reported
How to read it carefully
Confirm the complete study design, intervention identity, population or model, outcomes, statistical context, and limitations in the linked source before approval.
Research context only. This brief summarizes a published source and does not establish clinical efficacy, safety, dosing, or suitability for human or veterinary use. Review the original paper before drawing conclusions.
Read the original source · Drug discovery today